Wuhan YZY Biopharma Management
Management criteria checks 3/4
Wuhan YZY Biopharma's CEO is Pengfei Zhou, appointed in Mar 2018, has a tenure of 6.83 years. total yearly compensation is CN¥2.47M, comprised of 83% salary and 17% bonuses, including company stock and options. directly owns 3.54% of the company’s shares, worth HK$54.55M. The average tenure of the management team and the board of directors is 3.6 years and 4.6 years respectively.
Key information
Pengfei Zhou
Chief executive officer
CN¥2.5m
Total compensation
| CEO salary percentage | 83.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 3.5% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.6yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥184m |
| Mar 31 2024 | n/a | n/a | -CN¥188m |
| Dec 31 2023 | CN¥2m | CN¥2m | -CN¥192m |
| Sep 30 2023 | n/a | n/a | -CN¥189m |
| Jun 30 2023 | n/a | n/a | -CN¥186m |
| Mar 31 2023 | n/a | n/a | -CN¥187m |
| Dec 31 2022 | CN¥2m | CN¥2m | -CN¥189m |
| Dec 31 2021 | CN¥13m | CN¥2m | -CN¥149m |
Compensation vs Market: Pengfei's total compensation ($USD337.84K) is about average for companies of similar size in the Hong Kong market ($USD348.23K).
Compensation vs Earnings: Pengfei's compensation has increased whilst the company is unprofitable.
CEO
Pengfei Zhou (57 yo)
6.8yrs
Tenure
CN¥2,466,000
Compensation
Dr. Pengfei Zhou, MD., Ph D., has been Chairman of the Board at Wuhan YZY Biopharma Co., Ltd. since September 2022 and has been its Chief Executive Officer since March 2018.He has been an Executive Direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.8yrs | CN¥2.47m | 3.54% HK$ 54.5m | |
| Senior Vice President of Quality | 5.1yrs | no data | no data | |
| Senior Director of the R&D Center and Supervisor | no data | no data | no data | |
| Senior Manager of Strategic Development Department & Joint Company Secretary | 2.2yrs | no data | no data | |
| Joint Company Secretary | 1.6yrs | no data | no data |
3.6yrs
Average Tenure
49yo
Average Age
Experienced Management: 2496's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 10.3yrs | CN¥2.47m | 3.54% HK$ 54.5m | |
| Senior Director of the R&D Center and Supervisor | 6.9yrs | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥71.00k | no data | |
| Non-Executive Director | 2.3yrs | no data | no data | |
| Non-Executive Director | 7yrs | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥71.00k | no data | |
| Chairman of the Supervisory Committee | 7yrs | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥71.00k | no data | |
| Non-Executive Director | 14.5yrs | no data | 5.26% HK$ 81.0m | |
| Non-Executive Director | 14.5yrs | no data | 10.52% HK$ 162.0m | |
| Independent Non-Executive Director | 2.2yrs | CN¥71.00k | no data | |
| Non-Executive Director | 2.3yrs | no data | no data |
4.6yrs
Average Tenure
49.5yo
Average Age
Experienced Board: 2496's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 06:39 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wuhan YZY Biopharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|